Ghost Tree Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Ghost Tree Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-185,000	Closed	-$12.5M	–	54
2019 Q3	$12.5M	Buy	+185,000	New	+$14.2M	3.18%	15
2016 Q4	–	Sell	-60,000	Closed	-$5.55M	–	73
2016 Q3	$5.55M	Sell	60,000 -50,000	-45%	-$4.71M	0.9%	40
2016 Q2	$8.56M	Buy	110,000 +70,000	+175%	+$5.95M	2.47%	9
2016 Q1	$3.3M	Buy	+40,000	New	+$3.25M	1.87%	22
2015 Q2	–	Sell	-35,000	Closed	-$4.36M	–	75
2015 Q1	$4.36M	Sell	35,000 -5,000	-13%	-$530K	1.57%	22
2014 Q4	$3.62M	Buy	+40,000	New	+$3.33M	1.74%	24
2014 Q1	–	Sell	-20,000	Closed	-$1.41M	–	67
2013 Q4	$1.41M	Buy	+20,000	New	+$1.36M	0.87%	40

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Ghost Tree Capital's BMRN Position: Q4 2019 in Review

Ghost Tree Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2019, closing a stake of 185,000 shares — an estimated $12.5M sold.

Ghost Tree Capital first reported a position in BMRN in Q4 2013 and held it in 7 quarters. The position peaked at $12.5M in Q3 2019. 468 funds tracked by Wall St. Rank hold BMRN as of Q4 2019.

Ghost Tree Capital reported no remaining BioMarin Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Ghost Tree Capital sold 185,000 BioMarin Pharmaceuticals shares in Q4 2019, an estimated $12.5M.
Ghost Tree Capital first reported a position in BioMarin Pharmaceuticals in Q4 2013 and held it in 7 quarters.
Ghost Tree Capital's BioMarin Pharmaceuticals position peaked at $12.5M in Q3 2019.
468 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2019.

Based on Ghost Tree Capital's 13F filing for Q4 2019, filed 14 Feb 2020.